Compare Fidelity National Information Servcs Inc (FIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Sana Biotechnology Inc — how do they compare? Fidelity National Information Servcs Inc trades at $41.85 (market cap $21.24B), while Sana Biotechnology Inc trades at $3.41 (market cap $987.94M). The key difference: Fidelity National Information Servcs Inc is far larger — about 21.5× Sana Biotechnology Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.09% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FIS | SANA | |
|---|---|---|
Market Cap | $21.24B | $987.94M |
Sector | Technology | Health |
52-Week High | $81.94 | $5.92 |
52-Week Low | $37.72 | $2.68 |
Enterprise Value | $41.63B | $962.13M |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $40.58, down 3.22% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $1.36 versus $1.29, and analyst consensus remains strong with 21 Buy ratings and a $52.57 price target. Recent business developments include winning Frankfurt International Bank as a cloud banking client and receiving industry awards for AI-embedded risk technology.
The outlook presents a value opportunity with a low P/E of 7.97 and improving profit margins, though execution risks persist from the Worldpay divestiture and net cash flow volatility. Upside potential exists if the company capitalizes on its $42 billion market opportunity in digital payments and maintains its recent earnings momentum.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
